12th International Workshop on Clinical Pharmacology of Tuberculosis Drugs – Presentations

 

Tuesday, 10 September 2019

 Session 1: Pharmacokinetics and Pharmacodynamics of New and Repurposed TB Drugs
 Oxazolidinones for TB: Current Status and Future Prospects
Dr. Lawrence Geiter
  
 Oral Abstract Presentations
 Evaluating Hepatotoxicity of Bedaquiline Treatment in Multi-Drug Resistant Tuberculosis Patients
Lénaïg Tanneau
 
 Relationship Between Plasma and Intracellular Concentrations of Bedaquiline and its M2 Metabolite in South African Patients with Drug-Resistant TB
Precious Ngwalero
 
 Co-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial
Dr. Elisa Ignatius
 
 Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB
Dr. Ahmed Aliyu Abulfathi
 
 
 Session 2: Pharmacokinetics and Pharmacodynamics of Established TB Drugs
 Oral Abstract Presentations
 Pharmacogenetics and Pharmacokinetics of First-Line Anti-Tuberculosis Drugs in the HIRIF Trial
(Not yet available)

Dr. Elizabeth Mackay
 Increased Bactericidal Activity but Dose-Limiting Tolerability at 50 mg/kg Rifampicin
(No permission to publish slides)

Dr. Lindsey Te Brake
 
 Ethionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis
Dr. Charles Peloquin
 
 Exposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial
Dr. Chishala Chabala
 
 The OptiRIF Study: Pharmacokinetics of High-Dose Rifampicin in Children
(Not yet available)
Dr. Elin Svensson
 
   
 Session 3: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Modelling
 Pharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO
Dr. Ernesto Jaramillo
  
 Oral Abstract Presentations
 Can Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis
Dr. Frank Kloprogge
 
 PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312
Kamunkhwala Gausi
 
 Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis
Dr. Charles Peloquin
 
 Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM
Dr. Mathieu Bolhuis
 
   
 Session 4:  TB Drug Development and Optimization: Approaches and Tools
 

Combined use of Biomarker Data and Drug Exposures to Predict TB Treatment Response
(Not yet available)
Dr. Elin Svensson

  
 Oral Abstract Presentations
 An Assay to Measure Drug Tolerance of M. Tuberculosis in the Caseous Center of Pulmonary Lesions
(No permission to publish slides)
Jansy Sarathy
 
 A PBPK Modelling Approach to Simulate the Rifampicin-Moxifloxacin Drug-Drug Interaction in TB Patients
(No permission to publish slides)
Carlijn Litjens
 
 Stratified Dosage Regimens from Early Bactericidal Activity Studies: An Application to Pretomanid
(No permission to publish slides)
Dr. Michael Lyons
 
 Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients
Alan Faraj